What is PONLIMSI?

PONLIMSI is an FDA-approved interchangeable biosimilar that can be substituted for Prolia, whether you're new to therapy or currently taking Prolia.

What is a biosimilar?

A biosimilar is a biologic medication. It is highly similar to a biologic medication already approved by the FDA—the original biologic (also called the reference product).


To learn more about biosimilars, visit fda.gov.

PONLIMSI has been carefully tested and approved by the FDA as a biosimilar to Prolia

How are PONLIMSI and Prolia similar?

Triatomic molecule icon

PONLIMSI and Prolia work in the same way

Molecular graph icon

PONLIMSI and Prolia have no meaningful differences in safety and effectiveness

Pre-filled syringe icon

PONLIMSI and Prolia are given at the same strength and dosage

PONLIMSI is used to treat the same conditions as Prolia

PONLIMSI can be taken in place of Prolia to:

It is not known if PONLIMSI is safe and effective in children. PONLIMSI is not approved for use in children.

PONLIMSI is taken the same way as Prolia

TAKING PONLIMSI